Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project

Zaira R Palacios-Baena, Lucia Valiente de Santis, Natalia Maldonado, Clara M Rosso-Fernández, Irene Borreguero, Carmen Herrero-Rodríguez, Salvador López-Cárdenas, Franciso J Martínez-Marcos, Andrés Martín-Aspas, Patricia Jiménez-Aguilar, Juan J Castón, Francisco Anguita-Santos, Guillermo Ojeda-Burgos, M Pilar Aznarte-Padial, Julia Praena-Segovia, Juan E Corzo-Delgado, M Ángeles Esteban-Moreno, Jesús Rodríguez-Baño, Pilar Retamar, Zaira R Palacios-Baena, Lucia Valiente de Santis, Natalia Maldonado, Clara M Rosso-Fernández, Irene Borreguero, Carmen Herrero-Rodríguez, Salvador López-Cárdenas, Franciso J Martínez-Marcos, Andrés Martín-Aspas, Patricia Jiménez-Aguilar, Juan J Castón, Francisco Anguita-Santos, Guillermo Ojeda-Burgos, M Pilar Aznarte-Padial, Julia Praena-Segovia, Juan E Corzo-Delgado, M Ángeles Esteban-Moreno, Jesús Rodríguez-Baño, Pilar Retamar

Abstract

Introduction: Ceftaroline, tedizolid, dalbavancin, ceftazidime-avibactam and ceftolozane-tazobactam are novel antibiotics used to treat infections caused by multidrug-resistant pathogens (MDR). Their use should be supervised and monitored as part of an antimicrobial stewardship programme (ASP). Appropriate use of the new antibiotics will be improved by including consensual indications for their use in local antibiotic guidelines, together with educational interventions providing advice to prescribers to ensure that the recommendations are clearly understood.

Methods and analysis: This study will be implemented in two phases. First, a preliminary historical cohort (2017-2019) of patients from 13 Andalusian hospitals treated with novel antibiotics will be analysed. Second, a quasiexperimental intervention study will be developed with an interrupted time-series analysis (2020-2021). The intervention will consist of an educational interview between prescribers and ASP leaders at each hospital to reinforce the proper use of novel antibiotics. The educational intervention will be based on a consensus guideline designed and disseminated by leaders after the retrospective cohort data have been analysed. The outcomes will be acceptance of the intervention and appropriateness of prescription. Incidence of infection and colonisation with MDR organisms as well as incidence of Clostridioides difficile infection will also be analysed. Changes in prescription quality between periods and the safety profile of the antibiotics in terms of mortality rate and readmissions will also be measured.

Ethics and dissemination: Ethical approval will be obtained from the Andalusian Coordinating Institutional Review Board. The study is being conducted in compliance with the protocol and regulatory requirements consistent with International Council of Harmonisation E6 Good Clinical Practice and the ethical principles of the latest version of the Declaration of Helsinki. The results will be published in peer-reviewed journals and disseminated at national and international conferences.

Trial registration number: NCT03941951; Pre-results.

Keywords: audit; bacteriology; education & training (see medical education & training); infectious diseases; microbiology.

Conflict of interest statement

Competing interests: ZRPB reports personal fees from Gilead for educational purposes outside the submitted work. PRG and JRB participated in accredited educational activities supported by Merck through unrestricted grants outside the submitted work.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Timeline of NEW_SAFE project.

References

    1. Tacconelli E, Carrara E, Savoldi A, et al. . Discovery, research, and development of new antibiotics: the who priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018;18:318–27. 10.1016/S1473-3099(17)30753-3
    1. Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS One 2017;12:e0189621. 10.1371/journal.pone.0189621
    1. Neill J. Tackling drug-resistant infections globally: final report and recommendations [Internet]. Available:
    1. Global action plan on antimicrobial resistance. Available:
    1. Plan estrategico Y de acción para reducir El riesgo de selección Y diseminación de resistencia a Los antibióticos. 2016. P. 4–6. Available:
    1. Rodríguez-Baño J, Paño-Pardo JR, Alvarez-Rocha L, et al. . Programas de optimización de uso de antimicrobianos (ProA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH Y SEMPSPH. Enferm Infecc Microbiol Clin 2012;30:22.e1–22.e23. 10.1016/j.eimc.2011.09.018
    1. Rodríguez-Baño J, Cisneros JM, Cobos-Trigueros N, et al. . Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. guidelines of the Spanish Society of infectious diseases and clinical microbiology. Enferm Infecc Microbiol Clin 2015;33:337.e1–337.e21. 10.1016/j.eimc.2014.11.009
    1. Rodriguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, et al. . Treatment of infections caused by extended-spectrum-beta-. Clin Microbiol Rev 2018;31:1–42.
    1. Mensa J, Soriano A, Llinares P, et al. . [Guidelines for antimicrobial treatment of the infection by Staphylococcus aureus]. Rev Esp Quimioter 2013;26 Suppl 1:1–84.
    1. Zasowski EJ, Trinh TD, Claeys KC, et al. . Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother 2017;61:1–26. 10.1128/AAC.02015-16
    1. Cosimi RA, Beik N, Kubiak DW, et al. . Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review. Open Forum Infect Dis 2017;4:1–7. 10.1093/ofid/ofx084
    1. Si S, Durkin MJ, Mercier MM, et al. . Successful treatment of prosthetic joint infection due to vancomycin-resistant enterococci with tedizolid. Infect Dis Clin Pract 2017;25:105–7. 10.1097/IPC.0000000000000469
    1. Poulakou G, Lagou S, Karageorgopoulos DE, et al. . New treatments of multidrug-resistant gram-negative ventilator-associated pneumonia. Ann Transl Med 2018;6:423. 10.21037/atm.2018.10.29
    1. Peghin M, Maiani M, Castaldo N, et al. . Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant. Infection 2018;46:263–5. 10.1007/s15010-017-1086-0
    1. Vickery SB, McClain D, Wargo KA. Successful use of Ceftolozane-Tazobactam to treat a pulmonary exacerbation of cystic fibrosis caused by multidrug-resistant Pseudomonas aeruginosa. Pharmacotherapy 2016;36:e154–9. 10.1002/phar.1825
    1. Plant AJ, Dunn A, Porter RJ. Ceftolozane-Tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia. Expert Rev Anti Infect Ther 2018;16:367–8. 10.1080/14787210.2018.1473079
    1. Gaibani P, Campoli C, Lewis RE, et al. . In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother 2018;73:1525–9. 10.1093/jac/dky082
    1. Tansarli GS, Rafailidis PI, Kapaskelis A, et al. . Frequency of the off-label use of antibiotics in clinical practice: a systematic review. Expert Rev Anti Infect Ther 2012;10:1383–92. 10.1586/eri.12.137
    1. Davido B, Bouchand F, Calin R, et al. . High rates of off-label use in antibiotic prescriptions in a context of dramatic resistance increase: a prospective study in a tertiary hospital. Int J Antimicrob Agents 2016;47:490–4. 10.1016/j.ijantimicag.2016.04.010
    1. Septimus EJ. Antimicrobial resistance: an Antimicrobial/Diagnostic stewardship and infection prevention approach. Med Clin North Am 2018;102:819–29. 10.1016/j.mcna.2018.04.005
    1. Xu YL, Hu LM, Xie ZZ, et al. . [Impact of antimicrobial stewardship program on antimicrobial usage and detection rate of multidrug-resistant gram-negative bacteria]. Zhonghua Er Ke Za Zhi 2019;57:553–8. 10.3760/cma.j.issn.0578-1310.2019.07.012
    1. Magiorakos A-P, Srinivasan A, Carey RB, et al. . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81. 10.1111/j.1469-0691.2011.03570.x
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. . Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. 10.1136/bmj.e7586
    1. Cassini A, Högberg LD, Plachouras D, et al. . Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis 2019;19:56–66. 10.1016/S1473-3099(18)30605-4
    1. Harris AD, McGregor JC, Perencevich EN, et al. . The use and interpretation of quasi-experimental studies in medical informatics. J Am Med Inform Assoc 2006;13:16–23. 10.1197/jamia.M1749
    1. Schweitzer VA, van Werkhoven CH, Rodríguez Baño J, et al. . Optimizing design of research to evaluate antibiotic stewardship interventions: consensus recommendations of a multinational Working group. Clin Microbiol Infect 2020;26:41–50. 10.1016/j.cmi.2019.08.017
    1. Molina J, Peñalva G, Gil-Navarro MV, et al. . Long-Term impact of an educational antimicrobial stewardship program on hospital-acquired candidemia and multidrug-resistant bloodstream infections: a quasi-experimental study of interrupted time-series analysis. Clin Infect Dis 2017;65:1992–9. 10.1093/cid/cix692
    1. DiazGranados CA. Prospective audit for antimicrobial stewardship in intensive care: impact on resistance and clinical outcomes. Am J Infect Control 2012;40:526–9. 10.1016/j.ajic.2011.07.011

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir